Skip to main content

Table 4 Univariate and multivariate survival analysis in 26 osteosarcoma patients who treated with adjuvant chemotherapy

From: Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma

Characteristics

No.

OS

  

RFS

 
  

HR (95% CI)

P

 

HR (95% CI)

P

Univariate analysis

 SIRT6, positive (vs. negative)

15/26

5.855 (1.290-26.563)

0.022

 

4.523 (1.245–16.434)

0.022

Multivariate analysis

 Tumor size, > 8 cm (vs. ≤ 8 cm)

    

3.560 (1.055–12.009)

0.041

 Distant metastasis, presence (vs. absence)

 

48.868 (2.759-865.448)

0.008

 

10.649 (1.186–95.614)

0.035

 SIRT6, positive (vs. negative)

 

6.988 (1.439–33.930)

0.016

 

6.930 (1.727–27.814)

0.006

  1. OS overall survival; RFS relapse-free survival; HR hazard ratio; 95% CI 95% confidence interval. The variables included in multivariate analysis were age, tumor size, stage, lymph node metastasis, distant metastasis, histologic grade, and SIRT6 expression